[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 80 of about 80
1. Frydenberg M, Wijesinha S: Diagnosing prostate cancer - what GPs need to know. Aust Fam Physician; 2007 May;36(5):345-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DISCUSSION: Prostate cancer rarely causes symptoms in the early stage and lower urinary tract symptoms (LUTS) are more likely to be due to benign prostate disease rather than cancer.
  • [MeSH-major] Family Practice / methods. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Risk Assessment / methods
  • [MeSH-minor] Adult. Aged. Australia. Biomarkers, Tumor / blood. Biopsy, Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Digital Rectal Examination. Humans. Male. Mass Screening / organization & administration. Middle Aged. Palpation. Practice Patterns, Physicians'. Prostate-Specific Antigen / blood. Quality Assurance, Health Care

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492070.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 13
  •  go-up   go-down


2. Okada Y, Arakaki R, Kitahara M, Terada N, Kaneko Y, Oomori K, Nishimura K: [Two cases of the nephrogenic adenoma of the bladder]. Hinyokika Kiyo; 2005 Jul;51(7):467-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephrogenic adenoma is a relatively rare, benign tumor of the urinary tract.
  • Transurethral resection of the bladder tumor (TUR-Bt) was performed.
  • The second patient was a 72-year-old man who had a history of TUR-Bt for the bladder tumor and a history of left nephroureterectomy for left ureteral tumor.
  • Cystoscopy showed a papillary tumor on the top of the bladder wall and TUR-Bt was performed.
  • In both cases, the histopathological diagnosis was the nephrogenic adenoma.
  • [MeSH-major] Adenoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119812.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


3. Godley PA, Carpenter WR: Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms. J Clin Epidemiol; 2007 Feb;60(2):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
  • Lower urinary tract symptoms (LUTS), often referred to as early prostate cancer symptoms, occur more often in benign prostatic hyperplasia (BPH), a more commonly diagnosed, nonmalignant disease.
  • [MeSH-major] Mass Screening / methods. Patient Selection. Prostatic Neoplasms / diagnosis. Urinary Tract Infections
  • [MeSH-minor] Biomarkers, Tumor / urine. Case-Control Studies. Digital Rectal Examination. Humans. Male. Odds Ratio. Prostate-Specific Antigen / urine. Risk. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208124.001).
  • [ISSN] 0895-4356
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 1 P60 MD00244-01; United States / NCI NIH HHS / CA / 1 U01 CA114629-01; United States / NCI NIH HHS / CA / R25T CA 57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Wan Q, Luo JD, Cai SL, Shen BH, Zhao WP, Zhang ZG, Xie LP, Shen ZJ: [Inverted urothelial papilloma: report of 151 cases]. Zhonghua Wai Ke Za Zhi; 2005 Jan 15;43(2):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical features, pathology, diagnosis and treatment of inverted urothelial papilloma.
  • The diagnosis could be established mainly by ultrasonic, intravenous urography, retrograde pyelography, cystoscope and pathology.
  • Among them, 7 cases who had the papilloma at upper urinary tract underwent nephroureterectomy except one.
  • One hundred and forty-four cases had the papilloma at low urinary tract, with 124 treated by transurethral bladder tumor resection (TURBT), among which 11 cases accompanying benign prostatic hyperplasia were treated by transurethral prostatic resection, 3 by transurethral resection of prostatic urethral tumor, 15 by partial cystectomy, 2 by total cystectomy.
  • CONCLUSIONS: Inverted urothelial papilloma is a benign tumor, which appears male predominant.
  • [MeSH-major] Papilloma, Inverted / diagnosis. Papilloma, Inverted / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771817.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Boybeyi O, Karnak I, Orhan D, Ciftci AO, Tanyel FC, Kale G, Senocak ME: Cystic nephroma and localized renal cystic disease in children: diagnostic clues and management. J Pediatr Surg; 2008 Nov;43(11):1985-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Cystic nephroma (CN) and localized renal cystic disease (LRCD) are rare benign renal entities that can occur in children.
  • A retrospective evaluation of the experience with these conditions was performed to emphasize the importance of differential diagnosis, recognition, and selection of the proper mode of treatment.
  • The presenting symptoms were palpable mass in patients with CN and urinary tract infection in the patient with LRCD without impairment of renal function.
  • The presumptive diagnosis of CN prompts surgical intervention.
  • [MeSH-major] Kidney Diseases, Cystic / diagnosis. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Case Management. Child, Preschool. Diagnosis, Differential. Diagnostic Imaging. Female. Humans. Infant. Male. Nephrectomy. Remission Induction. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18970929.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • [MeSH-major] Carcinoma / pathology. Granuloma, Plasma Cell / pathology. Sarcoma / pathology. Urogenital Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


7. Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep; 2009 Nov;22(5):1149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of CD24 expression by immunohistochemistry was 68% in all the carcinomas of the breast, female genital tract, gastrointestinal tract, biliary tract and pancreas, urinary system, prostate and skin.
  • Overall, CD24 was more frequently overexpressed in their carcinomas than their benign lesions (OR=4.21; 95% CI, 1.826-9.731; P=0.001) and was significantly associated with lymph node metastasis (OR=2.41; CI, 1.013-5.720; P=0.047), advanced clinical stages (OR=1.59; 95% CI, 1.244-2.032; P<0.001) and shortened overall survival (HR=2.13; 95% CI, 1.656-2.730; P<0.001).
  • CD24 was more frequently and strongly expressed in breast (OR=35.80; 95% CI, 8.907-143.921; P<0.001) and ovarian carcinomas (OR=35.92; CI, 7.156-180.311; P<0.001), than in their benign counterparts.
  • In particular, CD24 may promote cancer development and progression in the breast, ovary and urinary bladder.
  • [MeSH-major] Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787233.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Tiwari P, Tripathi A, Vijay M, Mitra B, Kumar S, Pal DK, Kundu AK: Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience. Indian J Cancer; 2010 Oct-Dec;47(4):418-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience.
  • AIMS: Inverted papilloma (IP) is an uncommon benign neoplasm of the urinary tract.
  • In this study, we review all cases of urinary bladder IP in our institution and determine the need for strict follow-up.
  • MATERIALS AND METHODS: We included consecutive patients from August 2004 to August 2008 with IP of the urinary bladder in this study who did not have prior or concurrent urothelial carcinoma.
  • No patient had a synchronous or previous bladder tumor.
  • CONCLUSIONS: We conclude that when diagnosed by strictly defined criteria, IP as benign urothelial neoplasm was with extremely low incidence of recurrence and good prognosis.
  • [MeSH-major] Papilloma, Inverted / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131756.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, Stoerkel S, Blaszyk H, Cheville J, Sauter G, Wild PJ, Stoehr R, Hofstaedter F, Hartmann A: Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol; 2007 Jun;31(6):938-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.
  • AIM: Inverted papilloma (IP) of the urinary tract can be difficult to distinguish from noninvasive urothelial carcinoma with prominent inverted growth pattern (invNIUC).
  • CONCLUSIONS: IP is a benign lesion that lacks specific genetic alterations found in exophytic noninvasive papillary urothelial tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Papilloma, Inverted / genetics. Papilloma, Inverted / pathology. Urologic Neoplasms / genetics. Urologic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma / pathology. DNA Mutational Analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Loss of Heterozygosity. Microsatellite Repeats. Middle Aged. Observer Variation. Polymerase Chain Reaction. Receptor, Fibroblast Growth Factor, Type 3 / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527084.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


10. Srivastava S, Roy R, Singh S, Kumar P, Dalela D, Sankhwar SN, Goel A, Sonkar AA: Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark; 2010;6(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urinary bladder cancer is a major epidemiological problem that continues to grow each year.
  • In this pilot study, utility of non-invasive (1)H NMR spectroscopy has been evaluated for probing the metabolic perturbations occurring in non-muscle invasive urinary bladder cancer. (1)H NMR spectra of urine of bladder cancer patients and controls (healthy and urinary tract infection/bladder stone) (n = 103) were acquired at 400MHz.
  • The cancer patients showed significant (p < 0.05) variations in concentration of hippurate and citrate as compared with healthy controls and benign controls.
  • [MeSH-major] Biomarkers, Tumor / urine. Early Detection of Cancer / methods. Magnetic Resonance Spectroscopy / methods. Taurine / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Protons. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. Taurine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20164538.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 1EQV5MLY3D / Taurine
  •  go-up   go-down


11. Wang J, Wang H, Tang G, Hou Z, Wang G: Transitional cell carcinoma of upper urinary tract vs. benign lesions: distinctive MSCT features. Abdom Imaging; 2009 Jan-Feb;34(1):94-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of upper urinary tract vs. benign lesions: distinctive MSCT features.
  • The transitional cell carcinoma (TCC) of the upper urinary tract is relatively uncommon.
  • The clinical presentation of TCCs and many other diseases of the upper urinary tract are nonspecific, and most of these lesions are usually necessary to be evaluated by computed tomography (CT) urography.
  • CT appearances of TCCs can be classified as papillary, infiltrating papillary, and diffusely infiltrating tumor.
  • Most TCCs of the upper urinary tract can be identified on the bases of characteristic CT appearances.
  • However, some benign lesions may mimic different categories of TCCs and should be taken into account for differentiating diagnosis.
  • The useful CT signs to make differential diagnosis involve enhanced pattern, location of lesion, induration of urinary tract, and range of thickening of urinary wall.
  • The three-dimension (3D) reconstructed images is useful in making differential diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Tomography, Spiral Computed / methods. Urologic Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Humans. Imaging, Three-Dimensional. Infant. Male. Middle Aged. Neoplasm Staging. Radiographic Image Interpretation, Computer-Assisted

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581162.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Loeb S, Lotan TL, Thornton K, Gearhart SL, Schoenberg MP: A case of gastrointestinal stromal tumor diagnosed on prostate biopsy. Nat Clin Pract Urol; 2009 Jan;6(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of gastrointestinal stromal tumor diagnosed on prostate biopsy.
  • BACKGROUND: A 56-year-old man initially presented to a local urologist with severe lower urinary tract symptoms and microhematuria.
  • The findings were suggestive of benign prostatic hyperplasia, and the patient received finasteride, tamsulosin, and underwent transurethral needle ablation of the prostate.
  • DIAGNOSIS: Gastrointestinal stromal tumor.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048005.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Medeiros LR, Stein AT, Fachel J, Garry R, Furness S: Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis. Int J Gynecol Cancer; 2008 May-Jun;18(3):387-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis.
  • To determine the efficacy, safety, and cost of laparoscopic surgery compared with laparotomy in women with ovarian tumors assumed to be benign.
  • Laparoscopy is associated with a reduction in the following: febrile morbidity, urinary tract infection, postoperative complications, postoperative pain, days in hospital, and total cost.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cost-Benefit Analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Length of Stay. Middle Aged. Pain, Postoperative / physiopathology. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692084.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


14. Miyamae K, Otsuka T, Otsuka Y, Nagayoshi M, Hamada Y: [Clinical study of bladder tamponade resulting from clots of blood]. Nihon Hinyokika Gakkai Zasshi; 2006 Jul;97(5):743-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We researched causes of the bleeding, characteristics of the patients, the laboratory data of coagulation system and treatments of our experience in managing patients.
  • RESULTS: 8 cases took anticoagulant drugs, 6 cases had medical history of cerebral infarction or cardiac infarction, 4 cases took anticholinergic drugs and 9 cases had benign prostate hypertrophy or urethral stricture.
  • Bleeding was due to bladder tumor in 9, prostate cancer in 1, radiation cystitis in 3, chronic cystitis in 1, malignant lymphoma in 1, idiopathic causes in 3 and unknown causes in 2 cases.
  • For the remaining cases, transurethral coagulation and resection of bladder tumor were used as the second line treatment, and furthermore, radical cystectomy was performed in 1 case.
  • CONCLUSION: According to progress aging society, the amounts of taken anticoagulant drugs and the patients who had lower urinary tract dysfunction may increase.
  • It may be suggested that the cases of bladder tamponade resulting from clots of blood without bladder tumor or radiation cystitis tend to increase.
  • [MeSH-major] Blood Coagulation. Hemorrhage / etiology. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898598.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


15. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Raumforderungen im kleinen Becken aus Sicht des Urologen.
  • Pelvic tumors originating from outside the urinary tract commonly invade the urogenital organs by direct extension mainly because of the close relationships between the pelvic organs.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • These are the symptoms that lead to the diagnosis of the primary tumor.
  • It has to be kept in mind that urogenital tumors with such symptoms have to be included in the differential diagnosis.
  • An example is the development of hydronephrosis, where the initial measure has to be the immediate relief of the obstruction through draining of either the kidney or the urinary bladder.
  • The possibility of eradicating the tumor is then to be discussed after relieving the obstruction.
  • [MeSH-major] Pelvic Neoplasms. Prostatic Hyperplasia. Prostatic Neoplasms. Urethral Neoplasms. Urinary Bladder Neoplasms
  • [MeSH-minor] Cystectomy. Cystoscopy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prostatectomy. Quality of Life. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Castillo O, Foneron A, Vitagliano G, Sánchez-Salas R, Díaz M, Fajardo M, Franco C: Bladder leiomyoma: case report. Arch Esp Urol; 2008 Jan-Feb;61(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Leiomyoma is a benign lesion which represents 0.04-0.5% of bladder tumors.
  • We performed a laparoscopic partial cistectomy locating the tumor and resecting it with simultaneous cystoscopic control, obtaining negative margins.
  • Immunohistochemistry was positive for Actine and Vimentine stablishing diagnosis.
  • Cd 1 17 (c-kit) was negative and ruled out a Gastrointestinal Stromal Tumor.
  • CONCLUSIONS: Leiomyoma is bladder's most common benign non epithelial tumor.
  • It origins from the smooth muscle bundles and at the urinary tract the most common localizations are kidney and bladder.
  • Clinical presentation depends on tumor size and localization.
  • Ultrasound is the most useful diagnostic tool and the pathological diagnosis is mandatory.
  • Surgery is the treatment of choice and technique depends on tumor size and localization.
  • [MeSH-major] Leiomyoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405038.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Galić J, Simunović D: Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. Coll Antropol; 2008 Dec;32(4):1195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of benign prostate hyperplasia was 23.1%, of prostatitis 5.1% and of prostate cancer 3.7%, which is within expected reported values.
  • Significant lower urinary tract symptoms were found in both subjects with benign prostate hyperplasia and prostatitis, showing a strong overlap of symptoms.
  • Also we found lower levels of vitamin D in subjects with benign prostate hyperplasia and prostate cancer.
  • [MeSH-major] Hormones / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / epidemiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Croatia / epidemiology. Humans. Male. Mass Screening. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19149228.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hormones
  •  go-up   go-down


18. Ho H, Chen YD, Tan PH, Wang M, Lau WK, Cheng C: Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience. Urology; 2006 Aug;68(2):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience.
  • OBJECTIVES: To review all cases of urinary bladder inverted papilloma (IP) in our institution and determine the need for cystoscopic surveillance.
  • IP is an uncommon benign tumor of the urinary tract.
  • No patient had a synchronous or previous bladder tumor.
  • CONCLUSIONS: Although our cases exhibited benign biologic behavior, the presence of cytologic atypia and suspicious urine cytology require exclusion of TCC with an inverted pattern.
  • [MeSH-major] Cystoscopy. Papilloma, Inverted / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904447.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE: Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics; 2010;3:58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Urothelial carcinoma (UC) can arise at any location along the urothelial tract, including the urethra, bladder, ureter, or renal pelvis.
  • Although tumors arising in these various locations have similar morphology, it is unclear whether the gene expression profiles are similar between the upper-tract (ureter and renal pelvis) and lower-tract (bladder and urethra) carcinomas.
  • METHODS: Fresh tumor tissue was collected from patients with bUC (n = 10) and benign mucosa from the bladder of individuals undergoing resection for non-UC conditions (n = 7).
  • CONCLUSIONS: We found that the gene expression profiles of UCs from the upper and lower tract were extremely similar, suggesting that similar pathogenic mechanisms likely function in the development of these tumors.
  • The differential expression of genes in the identified pathway may represent a new avenue for detection of upper-tract tumors.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Kidney Neoplasms / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Genetic Markers. Humans. Urinary Tract / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):59-63 [11408067.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40510-7 [11483609.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8241-6 [11719456.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2872-80 [12782593.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Jan 22;20(2):289-90 [14734327.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1474-80 [14973555.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2250-63 [14968109.001]
  • [Cites] Br J Urol. 1991 Jan;67(1):32-6 [1993274.001]
  • [Cites] Virchows Arch. 2006 May;448(5):604-11 [16525827.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jan;46(1):75-86 [17044051.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1346-50 [17322920.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3171-6 [17409424.001]
  • [Cites] J Urol. 2007 May;177(5):1715-20 [17437794.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000176 [18773095.001]
  • [Cites] Mutat Res. 2008 Nov 17;657(1):77-83 [18790077.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4674-81 [19470766.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Urol Res. 1996;24(4):239-44 [8873383.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] BMC Genomics. 2005;6:67 [15882461.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5740-7 [16115911.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):272-9 [16424895.001]
  • (PMID = 21159190.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC3022544
  •  go-up   go-down


20. Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, McCormick DL: Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice. Food Chem Toxicol; 2007 Jan;45(1):55-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the mid and high doses induced mortality associated with impaction of the test article in the gastrointestinal tract.
  • Histopathology identified the kidney (hydronephrosis) and urinary bladder (epithelial hyperplasia) as target tissues for resveratrol toxicity.
  • The incidences of both benign and malignant tumors in mice exposed to resveratrol were comparable to those in vehicle controls.
  • By contrast, the positive control article, p-cresidine, induced urinary bladder cancer in both sexes.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. P-CRESIDINE .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2001 Jul 25;494(1-2):107-13 [11423350.001]
  • [Cites] Cardiovasc Res. 2000 Aug 18;47(3):549-55 [10963727.001]
  • [Cites] Toxicol Pathol. 2001;29 Suppl:30-50 [11695560.001]
  • [Cites] J Nutr. 2002 Feb;132(2):257-60 [11823587.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):893-903 [11895924.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):369-73 [12065739.001]
  • [Cites] Pharmacol Res. 2002 Jun;45(6):499-505 [12162952.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1531-6 [12189197.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4945-54 [12208745.001]
  • [Cites] Toxicol Lett. 2002 Dec 15;136(2):133-42 [12425963.001]
  • [Cites] Mutat Res. 2002 Nov 26;521(1-2):29-35 [12438001.001]
  • [Cites] Pharm Res. 2002 Dec;19(12):1907-14 [12523673.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:145-50 [12628512.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2143-50 [12687016.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 3;309(4):1017-26 [13679076.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):953-7 [14578128.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):736-44 [14760392.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):188-94 [14657512.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2190-202 [15041740.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22727-37 [15020596.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1380-3 [15316568.001]
  • [Cites] J Chromatogr A. 1996 Apr 12;730(1-2):47-52 [8680595.001]
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21875-82 [9705326.001]
  • [Cites] Drugs Exp Clin Res. 1999;25(2-3):65-77 [10370867.001]
  • [Cites] Cancer Lett. 1999 Apr 1;137(2):123-30 [10374832.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):1-10 [10403535.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):20-4 [10448061.001]
  • [Cites] Mol Pharmacol. 1999 Oct;56(4):760-7 [10496959.001]
  • [Cites] Toxicol Sci. 2004 Dec;82(2):614-9 [15329443.001]
  • [Cites] Eur J Cancer Prev. 2005 Apr;14(2):139-42 [15785317.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):36-45 [15688416.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):194-201 [15688382.001]
  • [Cites] FASEB J. 2005 Jul;19(9):1193-5 [15837718.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):113-22 [16356836.001]
  • [Cites] Bioorg Med Chem. 2006 Mar 1;14(5):1437-43 [16249091.001]
  • [Cites] Curr Biol. 2006 Feb 7;16(3):296-300 [16461283.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):641-8 [16465368.001]
  • [Cites] Int J Toxicol. 2006 May-Jun;25(3):219-28 [16717037.001]
  • [Cites] J Agric Food Chem. 2000 Apr;48(4):1243-6 [10775379.001]
  • [Cites] Mutat Res. 2001 Sep 20;496(1-2):171-80 [11551493.001]
  • (PMID = 16965847.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / CN005135-000; United States / NCI NIH HHS / CN / N01 CN005135-000; United States / NCI NIH HHS / CN / N01-CN-05135
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Stilbenes; 0 / Tumor Suppressor Protein p53; 4C11L78UR3 / cresidine; 97C5T2UQ7J / Cholesterol; Q369O8926L / resveratrol
  • [Other-IDs] NLM/ NIHMS16493; NLM/ PMC1855246
  •  go-up   go-down


21. Jalpota Y, Tewari V, Madan R: Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report.
  • Nephrogenic adenoma is a rare benign tumour-like lesion within the urothelial mucosa of the urinary tract.
  • Clinically it mimics bladder neoplasm.
  • Definite diagnosis is established by histological examination of tumor.
  • Though it attains an extensive spread in bladder mucosa and has a high tendency to recur, the clinical course is benign.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms. Neoplasm Recurrence, Local / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933732.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Safaei Asl A: Benign multilocular cyst. Iran J Kidney Dis; 2009 Jan;3(1):54-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multilocular cyst.
  • Benign multilocular cyst is a rare benign multicystic renal tumor.
  • The usual clinical presentation is an asymptomatic abdominal mass in children and nonspecific symptoms such as abdominal pain, hematuria, and urinary tract infection in adults.
  • This report presents a case of benign multilocular cyst in an 18-months-old boy admitted with abdominal distension and a palpable mass in his right loin.
  • The patient underwent right total nephrectomy, and histological findings were compatible with benign multilocular cyst.

  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377261.001).
  • [ISSN] 1735-8582
  • [Journal-full-title] Iranian journal of kidney diseases
  • [ISO-abbreviation] Iran J Kidney Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


23. Garrido Abad P, Coloma del Peso A, Jiménez Gálvez M, Herranz Fernández LM, Arellano Gañán R, Reina Durán T: [Inflammatory myofibroblastic tumor. Case report]. Arch Esp Urol; 2008 Jan-Feb;61(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory myofibroblastic tumor. Case report].
  • [Transliterated title] Tumor miofibroblástico inflamatorio vesical. Aportación de un nuevo caso.
  • OBJECTIVE: To report one case of myofibroblastic bladder tumor.
  • METHODS/RESULTS: We report the case of a 30-year-old woman with recurrent urinary tract infections and incidental finding of a bladder mass after abdominal ultrasound.
  • After TUR, inflammatory myofibroblastic tumor of the bladder was diagnosed.
  • CONCLUSION: Myofibroblastic tumor (also known as inflammatory pseudotumor or pseudosarcoma) is a benign tumor with mesenchymal origin.
  • It must not be misdiagnosed as a malignant neoplasm.
  • [MeSH-major] Leydig Cell Tumor / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405029.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Herawi M, Epstein JI: Solitary fibrous tumor on needle biopsy and transurethral resection of the prostate: a clinicopathologic study of 13 cases. Am J Surg Pathol; 2007 Jun;31(6):870-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor on needle biopsy and transurethral resection of the prostate: a clinicopathologic study of 13 cases.
  • One of the least commonly encountered spindle cell tumors seen on prostatic needle biopsy or transurethral resection (TUR) of the prostate is solitary fibrous tumor (SFT).
  • Mean patient age at diagnosis was 63 years (range: 46 to 75 y; median: 65 y).
  • Twelve men presented with urinary tract symptoms and 1 patient was biopsied during work-up of bone metastases.
  • In 9 cases, a complete tumor resection was attempted by cystoprostatectomy (n=2), radical prostatectomy (n=4), pelvic exenteration (n=2), or pelvic tumor resection (n=1).
  • Tumor sizes ranged from 8.5 to 15 cm in 7 radically resected cases.
  • Based on a combination of increased cellularity, mitotic activity, necrosis, nuclear pleomorphism, and infiltrativeness, 4 prostatic SFTs were malignant, 4 were benign, and 2 were borderline.
  • Three SFTs demonstrated >or=10% p53 immunoreactivity including 1 tumor with 50% positivity; and 3 cases had Ki-67 rates of >or=20%.
  • SFTs must be differentiated from other spindle cell neoplasms of the prostate especially from gastrointestinal stromal tumors that may arise from the rectal wall with invasion of the prostate or from the region between the rectum and the prostate.
  • [MeSH-major] Neoplasms, Fibrous Tissue / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Adhesion Molecules / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527073.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


25. Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF: Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia. Arch Ital Urol Androl; 2009 Mar;81(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
  • Benign prostatic hyperplasia (BPH) is a chronic common disease in many men and is often associated with bothersome lower urinary tract symptoms (LUTS).
  • In many men the disease presents with a progressive course that can result in complications such as acute urinary retention (AUR) and BPH-related surgery.
  • 5alpha-reductase inhibitors (5ARIs) display their effectiveness at long distance decreasing PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery.

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499750.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Azasteroids; 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; 0 / Sulfonamides; EC 3.4.21.77 / Prostate-Specific Antigen; G3P28OML5I / tamsulosin; O0J6XJN02I / Dutasteride
  • [Number-of-references] 57
  •  go-up   go-down


26. Lee SH, Mah SY, Chung BH: Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. J Endourol; 2010 Feb;24(2):271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms.
  • BACKGROUND AND PURPOSE: Inverted urothelial papilloma (IP) is an uncommon urothelial neoplasm.
  • We aimed to determine the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and lower urinary tract symptoms (LUTS).
  • PATIENTS AND METHODS: From 1994 to 2008, 53 patients with urinary IP underwent transurethral resection of the bladder tumor (TURBT) at our institution.
  • In IP located on the bladder neck of patients with benign prostatic hyperplasia (BPH), significantly higher obstructive symptoms and larger prostate volumes than that of other located IP with BPH were observed.
  • CONCLUSIONS: This is the largest series of cases of urinary bladder IP reported from Korea.
  • Despite the absence of agreement of its etiology, its presenting symptoms were related to LUTS and benign prostatic enlargement.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039831.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Dueñas García OF, Kerckoff Villanueva H, Rico Olvera H, Lira Plascencia J: [Benign peritoneal cystic mesothelioma as differential diagnose of an ovarian dependant tumor. Case report and review of the literature]. Ginecol Obstet Mex; 2007 Feb;75(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign peritoneal cystic mesothelioma as differential diagnose of an ovarian dependant tumor. Case report and review of the literature].
  • [Transliterated title] Mesotelioma quistico peritoneal benigno como diagnóstico diferencial de tumor dependiente del ovario. Comunicación de un caso y revisión bibliográfica.
  • Benign cystic mesothelioma is an uncommon lesion of the peritoneum, occurring predominantly in women of reproductive age.
  • The present case is a multitreated perimenopausal woman with lower urinary tract symptoms without clinical improvement despite the treatment, and pelvic pain with physical findings and radiology studies of a probable ovarian mass dependant tumoration, requiring protocolized exploratory laparotomy, finding a benign cystic mesothelioma.
  • [MeSH-major] Mesothelioma, Cystic / pathology. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Pelvic Pain / diagnosis. Pelvic Pain / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542260.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


28. Comeglio P, Chavalmane AK, Fibbi B, Filippi S, Marchetta M, Marini M, Morelli A, Penna G, Vignozzi L, Vannelli GB, Adorini L, Maggi M: Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest; 2010 Nov;33(10):730-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic inflammation is now considered a determinant of benign prostatic hyperplasia (BPH), promoting, together with the hormonal milieu, prostate overgrowth and lower urinary tract symptoms (LUTS).
  • The VDR agonist elocalcitol partially reverts COX-2 and IL-8 mRNA upregulation induced by a pro-inflammatory cytokine mixture (IL-17, interferon-γ, tumor necrosis factor-α) and inhibits cell migration in urethral cells.
  • CONCLUSIONS: Our results suggest that prostatic urethra is, within the lower urinary tract, a novel target for VDR agonists, as shown by the capacity of elocalcitol to inhibit ROCK activity and to limit inflammatory responses in human primary urethra cells.
  • [MeSH-minor] Aged. Cell Culture Techniques. Cells, Cultured. Cytokines / genetics. Cytokines / metabolism. Drug Evaluation, Preclinical. Gene Expression. Humans. Ligands. Male. Myocytes, Smooth Muscle / drug effects. Myocytes, Smooth Muscle / metabolism. Myocytes, Smooth Muscle / pathology. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49378-85 [14507914.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2576-83 [10902811.001]
  • [Cites] Mol Pharmacol. 2002 Feb;61(2):277-84 [11809851.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):948-54 [17696159.001]
  • [Cites] Nat Clin Pract Urol. 2008 Apr;5(4):211-9 [18301417.001]
  • [Cites] J Urol. 2001 Jul;166(1):172-6 [11435849.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2280-7 [15294940.001]
  • [Cites] J Cardiovasc Pharmacol. 2008 Oct;52(4):369-74 [18841072.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1131-46 [12920242.001]
  • [Cites] Prostate. 2002 Jun 1;52(1):43-58 [11992619.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3551-61 [9452482.001]
  • [Cites] J Urol. 2004 Aug;172(2):748-52 [15247775.001]
  • [Cites] Recent Results Cancer Res. 2003;164:29-42 [12899512.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3366-76 [18975348.001]
  • [Cites] Obstet Gynecol. 1989 Jul;74(1):69-74 [2733945.001]
  • [Cites] Eur Urol. 2002 Jul;42(1):1-6 [12121721.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1883-93 [16624828.001]
  • [Cites] Prostate. 2009 Apr 1;69(5):480-93 [19107880.001]
  • [Cites] Trends Pharmacol Sci. 2001 Jan;22(1):32-9 [11165670.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jan;308(1):54-8 [14532355.001]
  • [Cites] World J Urol. 2005 Dec;23(6):362-7 [16283327.001]
  • [Cites] Radiol Clin North Am. 2006 Sep;44(5):749-56, ix [17030225.001]
  • [Cites] Eur Urol. 2007 May;51(5):1202-16 [17182170.001]
  • [Cites] Mol Hum Reprod. 2007 Mar;13(3):181-7 [17227815.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):8506-15 [10085083.001]
  • [Cites] J Surg Res. 2007 Oct;142(2):239-45 [17574271.001]
  • [Cites] BJU Int. 2003 Feb;91(3):196-200 [12581003.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):84-90 [9240186.001]
  • [Cites] Nat Clin Pract Rheumatol. 2008 Aug;4(8):404-12 [18594491.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):552-7 [17368184.001]
  • [Cites] World J Urol. 2002 Apr;19(6):390-396 [28386659.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):964-72 [17618043.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):591-603 [15080791.001]
  • [Cites] Neurourol Urodyn. 2004;23(7):618-22 [15382181.001]
  • [Cites] Atherosclerosis. 2008 Aug;199(2):237-47 [18436225.001]
  • [Cites] Can J Urol. 1994 Jan;1(1):1-4 [12834558.001]
  • [Cites] J Sex Med. 2009 Jan;6(1):91-106 [19170840.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):689-93 [17241782.001]
  • [Cites] Eur J Biochem. 1997 Nov 15;250(1):63-71 [9431991.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1180-7 [12730857.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2525-30 [16886660.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13578-84 [12574166.001]
  • [Cites] Prostate. 2007 Feb 15;67(3):234-47 [17163492.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 25;369(1):149-56 [18155661.001]
  • [Cites] Physiol Rev. 2003 Oct;83(4):1325-58 [14506307.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):962-72 [15572423.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E315-22 [16507601.001]
  • [Cites] Br J Pharmacol. 2003 Dec;140(7):1292-302 [14581180.001]
  • [Cites] Br J Pharmacol. 2003 Mar;138(5):757-66 [12642376.001]
  • [Cites] Pediatr Radiol. 2007 Sep;37(9):851-62; quiz 945 [17572890.001]
  • [Cites] J Endocrinol Invest. 2006 Jul-Aug;29(7):665-74 [16957418.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53 [14769832.001]
  • [Cites] Pharmacol Rev. 1993 Sep;45(3):253-308 [8248281.001]
  • [Cites] Pharmacol Rev. 2004 Dec;56(4):581-631 [15602011.001]
  • [Cites] J Immunol. 2007 Jan 1;178(1):145-53 [17182549.001]
  • [Cites] Urol Clin North Am. 2008 Feb;35(1):109-15; vii [18061029.001]
  • (PMID = 20386089.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BXL628; 0 / Cytokines; 0 / Ligands; 0 / Receptors, Calcitriol; FXC9231JVH / Calcitriol
  •  go-up   go-down


29. Sezer K, Cakal E, Ozkaya M, Yaman E, Akbay E: Normal CA 19-9 levels in Hashimoto's thyroiditis. Asian Pac J Cancer Prev; 2009 Apr-Jun;10(2):315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well known that moderately increased concentrations of CA 19-9 can be found in 15-36 % of patients with benign conditions such as pancreatic, liver, biliary diseases and benign hydronephrosis.
  • Patients with malignancy, benign pancreas, liver, lung and biliary diseases, inflammatory bowel diseases, urinary tract infection, hydronephrosis, endometriosis, diabetes mellitus and chronic renal failure were excluded.
  • Although the American Society of Clinical Oncology does not recommend tumor markers like CA 19-9 in screening for malignancies, they may be used for this purpose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537903.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


30. Delsignore A, Ranzoni S, Arancio M, Marchetti C, Landi G, Mina A, Marcato M, Martinengo C: Kidney hibernoma: case report and literature review. Arch Ital Urol Androl; 2010 Sep;82(3):189-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Hibernomas are rare benign tumours originating from the brown adipose tissue.
  • They are benign tumor that does not recur with complete excision.
  • Abdomen ultrasound and i.v. pyelografy showed pyelic stone of 2 cm without other pathologies of the urinary tract.
  • Definitive histological examination show a well-circumscribed, encapsulated tumor, with large cells with central nuclei and multivacuolated granular cytoplasm.
  • Histological diagnosis presumed hibernoma.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121442.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


31. Moyano Calvo JL, Maqueda Marín Mde L, Dávalos Casanova G, Sánchez de la Vega J, Giraldez Puig J, Huesa Ramírez FI, Maestro Durán JL, Ramírez Mendoza A, Morales López A: [Bladder leiomyoma in a 17-year-old male patient]. Arch Esp Urol; 2005 Nov;58(9):954-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Bladder leiomyoma is a rare tumor, its frequency being estimated below 1%.
  • METHODS: We report the case of a 17-year-old mole patient presenting with hematuria and lower urinary tract irritative symptoms whose work up discovered two small bladder tumors.
  • RESULTS: After TUR of the lesions the diagnosis of bladder leiomyoma was established; no recurrences have appeared on follow-up.
  • CONCLUSIONS: Bladder leiomyoma is a benign tumor, therefore surgery should be the most conservative.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430045.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 8
  •  go-up   go-down


32. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


33. Semins MJ, Schoenberg MP: A case of florid cystitis glandularis. Nat Clin Pract Urol; 2007 Jun;4(6):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytology revealed benign cells with numerous micro-organisms.
  • There were no upper urinary tract defects.
  • We performed cystoscopy with transurethral resection of the bladder tumor.
  • DIAGNOSIS: Pathology revealed cystitis glandularis.
  • [MeSH-major] Cystitis / radiography. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cystoscopy. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551538.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Chen HQ, Han CZ, Du LL, Cui Y, Pang DZ, Jing JX, Zhao XW, Tian BG, Mi ZG: [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22]. Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun;41 Suppl:84-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
  • OBJECTIVE: To evaluate the urinary nuclear matrix protein (NMP22) as an adjuvant diagnostic index for transitional cell carcinoma of urinary tract and monitoring the state of disease.
  • METHODS: Urinary samples were collected from 262 patients with transitional cell carcinoma, 198 non-transitional cell carcinoma of the urinary tract and 65 patients with benign diseases.
  • Urinary NMP22 concentration was determined through enzyme linked immunosorbent assay (ELISA).
  • RESULTS: The urinary NMP22 concentration had significant difference among the three groups (Kruskal Wallis, chi(2) = 197.17 P < 0.001).
  • The detection sensitivity and specificity of urinary NMP22 to transitional cell carcinoma were 71.37% and 87.69% respectively.
  • CONCLUSION: MP22 is a helpful tumor marker for the diagnosis of transitional cell carcinoma and monitoring the state of illness with increased efficacy.
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Transitional Cell / diagnosis. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767866.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


35. Ortiz Gorraiz M, Campaña Gutiérrez MA: [Subepithelial hematoma of the renal pelvis producing a filling defect in the upper urinary tract radiological study]. Arch Esp Urol; 2005 May;58(4):354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subepithelial hematoma of the renal pelvis producing a filling defect in the upper urinary tract radiological study].
  • [Transliterated title] Hematoma subepiteual de la pelvis renal como causa de defecto de repleción en el estudio radiológico del tracto urinario superior.
  • OBJECTIVES: After taking care of a patient with suspicion of upper urinary tract neoplasia which was finally diagnosed of renal pelvis subepithelial hematoma (Antopol-Goldman lesion), we decided to review such unfrequent pathology with the aim to summarize its main characteristics.
  • METHODS: The patient presented clinically and radiologically as an upper urinary tract tumor and underwent nephroureterectomy.
  • RESULTS: Pathologic study of the nephrectomy specimen reported absence of urothelial tumor and presence of a subepithelial hematoma of the renal pelvis, which explained both clinical manifestations and radiological findings.
  • CONCLUSIONS: Subepithelial hematoma of the renal pelvis is a benign lesion, more frequent in females, which appears between the fourth and sixth decades of life.
  • It simulates an upper urinary tract urothelial tumor, both clinically and radiologically, and so is treated in most published cases.
  • It is necessary to know this entity as possible differential diagnosis of upper urinary tract radiological study filling defects to avoid non necessary nephrectomies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989101.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


36. Fromont G, Barcat L, Gaudin J, Irani J: Revisiting the immunophenotype of nephrogenic adenoma. Am J Surg Pathol; 2009 Nov;33(11):1654-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephrogenic adenoma (NA) is a rare benign lesion of the urinary tract.
  • We assessed the expression of p63, cytokeratins 7 and 20, CD10 (proximal tubule marker), MUC1 (distal tubule marker), PAX2, and AMACR on 14 NAs (from 6 patients) grouped on a tissue microarray.
  • [MeSH-major] Adenoma / immunology. Immunophenotyping / methods. Urologic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Indirect. Humans. Kidney Tubules / enzymology. Male. Middle Aged. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / metabolism. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730362.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


37. Jønler M, Eddy B, Poulsen J: Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol; 2005;39(3):214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Prostate-specific antigen (PSA) is a well-known and -utilized tumor marker for prostate cancer.
  • Elevated PSA values are not specific for prostate cancer as they may be caused by other benign conditions.
  • Only 28% of GPs measured PSA in all males complaining of lower urinary tract symptoms (LUTS).
  • PSA testing is not used as a standard test in men with LUTS, and patients are not referred to urologists at a sufficiently low PSA level to improve the early diagnosis and work-up of patients with suspected prostate cancer.
  • [MeSH-major] Clinical Competence. Needs Assessment. Physicians, Family / education. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood


38. Hostanska K, Suter A, Melzer J, Saller R: Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res; 2007 Mar-Apr;27(2):873-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phytotherapy is a third approach for treating lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
  • MATERIALS AND METHODS: The effect of an ethanolic extract of S. repens (10-1000 microg/ml) was tested in hormone-sensitive LNCaP, MCF-7 and hormone-insensitive DU 145, MDA MB231 prostate, breast carcinoma cell lines, renal Caki-1, urinary bladder J82, colon HCT 116 and lung A 549 cancer cells.
  • [MeSH-major] Apoptosis / drug effects. Fruit / chemistry. Neoplasms / drug therapy. Phytotherapy / methods. Plant Extracts / pharmacology. Serenoa / chemistry
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. HCT116 Cells. Humans. Male. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy


39. Bluemn EG, Paulson KG, Higgins EE, Sun Y, Nghiem P, Nelson PS: Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls. J Clin Virol; 2009 Feb;44(2):164-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls.
  • Although the transmission route for MCV is not yet known, other polyomaviruses, such as BKV, cause non-malignant pathology in the urinary tract.
  • STUDY DESIGN: RNA was extracted from 28 patient-matched cancerous and 28 benign prostate epithelial samples, and six additional cancer-adjacent stromal samples.
  • DNA and RNA from a sequence-verified MCV-containing MCC tumor served as a positive control.
  • RESULTS: No MCV T antigen was detected in prostate carcinomas, patient-matched benign samples, or tumor-adjacent stroma, with appropriate sensitivity of the assay demonstrated by an MCC tumor.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):832-41 [14576661.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):943-51 [15651057.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e25 [16609730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6 [16829574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60 [17234809.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):246-8 [18650846.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):375-81 [18280333.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] J Virol. 2008 Mar;82(6):2705-14 [18160432.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):277-83 [18823818.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7 [18812503.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):248-50 [18633441.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5033-41 [17510436.001]
  • (PMID = 19129009.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1 R25 CA94880-07; United States / NCI NIH HHS / CA / CA094880-07; United States / NCI NIH HHS / CA / U54 CA119338-03; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / R25 CA094880-07; United States / NCI NIH HHS / CA / CA080416-10; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / T32 CA080416-10; United States / NCI NIH HHS / CA / T32 CA80416-10; United States / NCI NIH HHS / CA / T32 CA080416; United States / NCI NIH HHS / CA / CA119338-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / RNA, Messenger; 0 / RNA, Viral
  • [Other-IDs] NLM/ NIHMS99745; NLM/ PMC2676318
  •  go-up   go-down


40. Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E: Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol; 2009;11(2):82-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1320-8 [19297566.001]
  • [Cites] Kidney Int. 2004 Feb;65(2):386-92 [14717908.001]
  • [Cites] J Urol. 2009 Feb;181(2):817-22; discussion 822 [19110267.001]
  • [Cites] J Urol. 2009 Feb;181(2):518-23; discussion 523 [19100579.001]
  • [Cites] J Urol. 2009 Feb;181(2):647-57 [19091354.001]
  • [Cites] J Urol. 2009 Feb;181(2):701-4 [19091340.001]
  • [Cites] J Urol. 2009 Feb;181(2):694-700 [19091335.001]
  • [Cites] J Urol. 2009 Feb;181(2):506-11 [19084868.001]
  • [Cites] J Urol. 2009 Feb;181(2):585-91; discussion 591-3 [19084860.001]
  • [Cites] J Urol. 2009 Jan;181(1):379-86 [19010489.001]
  • [Cites] J Urol. 2009 Jan;181(1):161-6 [19013593.001]
  • [Cites] J Urol. 2009 Jan;181(1):9-10 [19012934.001]
  • [Cites] J Urol. 2009 Jan;181(1):17-28 [19012920.001]
  • [Cites] J Urol. 2009 Jan;181(1):55-61; discussion 61-2 [19012918.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8 [18957682.001]
  • [Cites] J Urol. 2008 Nov;180(5):1959-62; discussion 1962-3 [18801532.001]
  • [Cites] Ann Intern Med. 2008 Aug 5;149(3):185-91 [18678845.001]
  • [Cites] BMC Med. 2008;6:19 [18611265.001]
  • [Cites] Semin Nephrol. 2008 Mar;28(2):174-80 [18359398.001]
  • [Cites] Urol Clin North Am. 2007 Aug;34(3):335-46 [17678984.001]
  • [Cites] Surg Obes Relat Dis. 2005 Sep-Oct;1(5):481-5 [16925274.001]
  • [Cites] JAMA. 2005 Jan 26;293(4):455-62 [15671430.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):501-9 [8701989.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] J Urol. 1988 Aug;140(2):401-4 [3398161.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2181-5, quiz 2435 [15126781.001]
  • [Cites] J Urol. 2004 Mar;171(3):1066-70 [14767272.001]
  • [Cites] J Urol. 2009 Feb;181(2):492-8; discussion 498-9 [19110280.001]
  • (PMID = 19680529.001).
  • [ISSN] 1523-6161
  • [Journal-full-title] Reviews in urology
  • [ISO-abbreviation] Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2725309
  • [Keywords] NOTNLM ; 4-Kallikrein panel / Benign prostatic hyperplasia / Benign prostatic specific antigen / Botulinum toxin type A / Enteric urologic surgery / Genitourinary pain index / Hormonal therapy / Inflammation / Laparoscopy for adrenal cortical carcinoma / Lower urinary tract symptoms / Male voiding dysfunction / Nephrolithiasis / Nephron-sparing surgery / Obesity / Partial adrenalectomy / Pediatric urethral stricture / Prostate cancer screening / Roux-en-Y gastric bypass surgery / Silodosin / Stress urinary incontinence / TMPRSS2:ERG / Tumor markers / UPOINT clinical phenotype system / Urethral trauma / Vesicoureteral reflux / Watchful waiting
  •  go-up   go-down


41. Fasih N, Prasad Shanbhogue AK, Macdonald DB, Fraser-Hill MA, Papadatos D, Kielar AZ, Doherty GP, Walsh C, McInnes M, Atri M: Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics; 2008 Nov-Dec;28(7):1931-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extrauterine leiomyomas are rarer, and they present a greater diagnostic challenge: These histologically benign tumors, which originate from smooth muscle cells, usually arise in the genitourinary tract (in the vulva, ovaries, urethra, and urinary bladder) but may arise in nearly any anatomic site.
  • In addition, unusual growth patterns may be seen, including benign metastasizing leiomyoma, disseminated peritoneal leiomyomatosis, intravenous leiomyomatosis, parasitic leiomyoma, and retroperitoneal growth.
  • In the presence of such a pattern, a synchronous uterine leiomyoma or a previous hysterectomy for removal of a primary uterine tumor may be indicative of the diagnosis.
  • [MeSH-major] Diagnostic Imaging / methods. Leiomyoma / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Rare Diseases / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19001649.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


42. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res; 2006 Jan 15;66(2):1234-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
  • Recent studies showed that 30% of men with high-grade prostate intraepithelial neoplasia (HG-PIN) would develop prostate cancer (CaP) within 1 year after repeated biopsy.
  • After 1 year, only one tumor was diagnosed among the 30 GTCs-treated men (incidence, approximately 3%), whereas nine cancers were found among the 30 placebo-treated men (incidence, 30%).
  • International Prostate Symptom Score and quality of life scores of GTCs-treated men with coexistent benign prostate hyperplasia improved, reaching statistical significance in the case of International Prostate Symptom Scores.
  • As a secondary observation, administration of GTCs also reduced lower urinary tract symptoms, suggesting that these compounds might also be of help for treating the symptoms of benign prostate hyperplasia.
  • [MeSH-major] Catechin / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatic Neoplasms / prevention & control. Tea


43. Fellegara G, Froio E, Luong TV, Campanini N, Facchini F, Cortellini P, Melissari M: A case of medullary sponge kidney (Cacchi-Ricci disease) mimicking a renal mass. Arch Ital Urol Androl; 2005 Dec;77(4):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medullary sponge kidney (MSK) is an uncommon benign congenital disorder, generally asymptomatic.
  • In symptomatic patients the diagnosis is usually made by excretory urography performed in the most frequent complications such as renal stones, urinary tract infections and haematuria.
  • When haematuria represents the only symptom, and radiographic findings are not characteristic of MSK, the differential diagnosis with a renal tumor can be very difficult.
  • We report a case of MSK that underwent nephrectomy since clinical and radiological features mimicked a renal tumor.

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Medullary sponge kidney.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444933.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Vaida M, Novac B, Gheorghiu V, Novac C: [New developments in the diagnosis of benign prostatic hyperplasia]. Rev Med Chir Soc Med Nat Iasi; 2006 Jan-Mar;110(1):88-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New developments in the diagnosis of benign prostatic hyperplasia].
  • [Transliterated title] Actualităţi în diagnosticul hiperplaziei benigne a prostatei.
  • The first phase in the diagnosis of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is to exclude another disease.
  • If, after the initial evaluation, the diagnosis is still uncertain, further investigations are necessary: imagistic exploration of the urinary tract, urodynamic tests or urethro-cystoscopy.
  • [MeSH-major] Prostatic Hyperplasia / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / blood. Cystoscopy. Diagnosis, Differential. Digital Rectal Examination / methods. Humans. Male. Medical History Taking. Physical Examination. Prostate-Specific Antigen / blood. Quality of Life. Severity of Illness Index. Urinalysis. Urination Disorders / etiology. Urodynamics

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292085.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 13
  •  go-up   go-down


45. Kim TK, Kim KH, Kim CH, Shin SW, Kwon JY, Kim HK, Baik SW: Percutaneous vertebroplasty and facet joint block. J Korean Med Sci; 2005 Dec;20(6):1023-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is surprising that about 24% of patients with benign osteoporotic vertebral fracture die within a year from respiratory infection and urinary tract infection because of coughing and voiding difficulties, depending on the sites of compression fractures.
  • The mean changes of numeric rating scale scores, Oswestry Disability Index except sex life, and Karnofsky performance status were -72.00, -83.50 and +60.62% in the osteoporosis group and -51.89, -45.02, and 69.03% in the tumor group.

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 2001 May;43(5):409-12 [11396748.001]
  • [Cites] Med Sci Monit. 2001 Sep-Oct;7(5):1108-17 [11535963.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):985-92 [11889149.001]
  • [Cites] Drugs Aging. 2002;19(1):43-78 [11929326.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):178-82 [2423224.001]
  • [Cites] Pain. 2003 Oct;105(3):387-92 [14527699.001]
  • [Cites] BMJ. 1996 May 18;312(7041):1254-9 [8634613.001]
  • [Cites] J Vasc Interv Radiol. 2002 Nov;13(11):1135-8 [12427813.001]
  • [Cites] J Vasc Interv Radiol. 2003 Jul;14(7):827-31 [12847189.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):1540-7; discussion 1548 [12865841.001]
  • [Cites] Radiology. 2003 Oct;229(1):27-36 [14519867.001]
  • [Cites] Am J Med. 1986 Sep;81(3):381-6 [2428242.001]
  • (PMID = 16361816.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2779303
  •  go-up   go-down


46. Montanari E, Del Nero A, Bernardini P, Mangiarotti B, Confalonieri S, Grisotto M, Cordima G: Percutaneous therapy of low stage and grade urothelial neoplasia: long-term follow up. Arch Ital Urol Androl; 2005 Dec;77(4):211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous therapy of low stage and grade urothelial neoplasia: long-term follow up.
  • Nephroureterectomy with the excision of the ipsilateral ureteral orifice and bladder cuff has been considered the standard treatment of the urinary upper transitional cell carcinoma.
  • With the advent of sophisticated techniques for the endo-urologic management of many benign urologic diseases of the upper tract, there has been growing enthusiasm for the application of these same techniques in the management of upper tract TCC, which is also supported by recent advances in the development of small calibre telescopes with improved optics and the development of small calibre adjunctive instruments and laser fibers.
  • A large number of cases published in the literature has confirmed the safety and efficacy of percutaneous treatment in selected patients with upper tract TCC of low grade and stage.
  • 4 pts (5 renal units: 4 T1G2 and 1 TaG1) underwent percutaneous resection for a tumor in a solitary kidney (2 cases), one case for bilateral neoplasm, and in the other case the lesion was unilateral with chronic renal failure.
  • After preoperative evaluation, (excretory urography, computerized tomography and ureteroscopy with biopsy to confirm the low stage and grade of the lesion) the tumor was resected using an Amplatz sheat of 26-30 Fr and a 24 Fr resectoscope to keep a low intra-caliceal pressure.
  • The tumor base was biopsied and fulgurated After 48 h, contrastography to assure integrity of the urinary system was performed and Mitomycin C was infused over 24 h.
  • Second-look nephroscopy with multiple biopsies was performed in all cases 7 days later and 8 Ch nephrostomy was placed.
  • All pts at a mean follow up of 71 months were tumor free.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444935.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. Zachariou AG, Manoliadis IN, Kalogianni PA, Karagiannis GK, Georgantzis DJ: A rare case of bladder fibroepithelial polyp in childhood. Arch Ital Urol Androl; 2005 Jun;77(2):118-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a rare case of a benign polyp in a child.
  • Very few cases of urinary tract fibroepithelial polyps in the bladder are reported in the international literature and they are even less common in children.
  • The patient did not report previous urinary tract disorders.
  • After a thorough laboratory investigation, which included urinalysis, urine culture, ultrasonography, intravenous pyelography and cystoscopy the presence of an exophytic papillary tumor in the bladder was identified.
  • RESULTS: The biopsy set the diagnosis of fibroepithelial polyp, which is a rare benign neoplasm and occurs in patients of nearly all ages.

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146277.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Bjornsson B, Birgisson G, Oddsdottir M: Laparoscopic adrenalectomies: A nationwide single-surgeon experience. Surg Endosc; 2008 Mar;22(3):622-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since then, all procedures for presumed benign lesions of the adrenals have been performed laparoscopically in a single center.
  • The preoperative diagnosis was documented, as well as the pathologic diagnosis, operative details, complications, and length of hospital stay.
  • The complications were mild pancreatitis (n = 1), urinary tract infection (n = 1), atelectasis (n = 1), mild congestive heart failure (n = 2), and transient corneal abrasion (n = 1).
  • The mean tumor size was 3.5 cm (range, 1.5-6.2 cm), and the mean postoperative hospital stay was 2.6 days (range, 1-6 days).
  • CONCLUSION: The results of laparoscopic adrenalectomies in Iceland for benign lesions of the adrenals are comparable with published results from large referral centers.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods. Laparoscopy / statistics & numerical data. Pheochromocytoma / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Iceland / epidemiology. Immunohistochemistry. Length of Stay. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Minimally Invasive Surgical Procedures / statistics & numerical data. Neoplasm Staging. Pain, Postoperative / physiopathology. Postoperative Complications / epidemiology. Probability. Reference Values. Retrospective Studies. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2005 Dec;138(6):1078-85; discussion 1085-6 [16360394.001]
  • [Cites] Surg Clin North Am. 1996 Jun;76(3):523-37 [8669012.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1342-6 [11038204.001]
  • [Cites] World J Surg. 1999 Apr;23(4):389-96 [10030863.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):199-203 [16490899.001]
  • [Cites] Surg Endosc. 1996 Oct;10(10):987-90 [8864091.001]
  • [Cites] ANZ J Surg. 2002 Jul;72(7):467-70 [12123501.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):405-8 [16498053.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] Surgery. 2006 Dec;140(6):914-20; discussion 919-20 [17188138.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):186-92 [15719374.001]
  • [Cites] World J Urol. 1999 Feb;17(1):48-53 [10096151.001]
  • [Cites] Endocr Relat Cancer. 2000 Mar;7(1):29-36 [10808194.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1259-74 [15376201.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):405-11 [15820450.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):621-5 [15026894.001]
  • (PMID = 18163169.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Levy BS: Modern management of uterine fibroids. Acta Obstet Gynecol Scand; 2008;87(8):812-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine fibroids are the most common tumor of the reproductive tract in women of reproductive age.
  • Although they are benign tumors that are often asymptomatic, uterine fibroids may cause debilitating symptoms in many women, such as abnormal uterine bleeding, abdominal pain, increased abdominal girth, urinary frequency, constipation, pregnancy loss, dyspareunia, and in some cases infertility.
  • The choice of approach may be dictated by factors such as the patient's desire to become pregnant in the future, the importance of uterine preservation, symptom severity, and tumor characteristics.
  • [MeSH-major] Leiomyoma / therapy. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607823.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reproductive Control Agents
  • [Number-of-references] 80
  •  go-up   go-down


50. Greenfield SP, Williot P, Kaplan D: Gross hematuria in children: a ten-year review. Urology; 2007 Jan;69(1):166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed our experience characterizing its clinical presentation and diagnosis.
  • RESULTS: Of the 272 male patients, 52 (19%) had benign urethrorrhagia; 48 (14%) had trauma; and 48 had a urinary tract infection (14%), and 10 of those also had urologic anomalies.
  • Also, 18 patients (5%) had stones; 3 had low-grade bladder transitional cell carcinoma; and 1 had a Wilms tumor.
  • CONCLUSIONS: Gross hematuria most often had a benign cause in children and adolescents.
  • Voiding cystourethrography is useful in those with suspicious ultrasound findings, urinary tract infection, or voiding symptoms.

  • Genetic Alliance. consumer health - TEN.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270642.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res; 2006 Jan 15;12(2):432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Urine samples collected preoperatively from postmenopausal women with ovarian cancer and benign conditions and from nonsurgical controls were analyzed by surface-enhanced laser desorption/ionization mass spectrometry and two-dimensional gel electrophoresis.
  • Quantitative and semiquantitative ELISAs were developed for preliminary validation in patients of 128 ovarian cancer, 52 benign conditions, 44 other cancers, and 188 healthy controls.
  • RESULTS: A protein (m/z approximately 17,400) with higher peak intensities in cancer patients than in benign conditions and controls was identified and subsequently defined as eosinophil-derived neurotoxin (EDN).
  • CONCLUSIONS: Specific elevated posttranslationally modified urinary EDN and osteopontin COOH-terminal fragments in ovarian cancer might lead to potential noninvasive screening tests for early diagnosis.
  • Urine with less complexity than serum and relatively high thermodynamic stability of peptides or metabolites is a promising study medium for discovery of the novel biomarkers which may present in many non-urinary tract neoplastic diseases.
  • [MeSH-major] Biomarkers, Tumor / urine. Eosinophil-Derived Neurotoxin / urine. Neoplasms, Glandular and Epithelial / urine. Ovarian Neoplasms / urine. Sialoglycoproteins / urine
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / urine. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / urine. Amino Acid Sequence. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Endometrioid / urine. Case-Control Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystadenocarcinoma, Serous / urine. Electrophoresis, Gel, Two-Dimensional. Enzyme-Linked Immunosorbent Assay. Female. Glycosylation. Humans. Molecular Sequence Data. Neoplasm Invasiveness. Osteopontin. Prognosis. Proteome. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jan 15;12(2):323-7 [16428467.001]
  • (PMID = 16428483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA 105009; United States / NCI NIH HHS / CA / R21 CA 111949-01; United States / NCI NIH HHS / CA / U01 CA 86381
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin; EC 3.1.- / Eosinophil-Derived Neurotoxin
  •  go-up   go-down


52. Boni L, Dionigi G, Cassinotti E, Di Giuseppe M, Diurni M, Rausei S, Cantore F, Dionigi R: Single incision laparoscopic right colectomy. Surg Endosc; 2010 Dec;24(12):3233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery has been fully validated as alternative, minimally invasive treatment for different benign and malignant conditions.
  • One patient had a postoperative urinary tract infection and one prolonged ileum that did not required any surgical intervention.
  • The mean postoperative stay was 5 ± 1.2 days (range, 4-14), and mean lymph node retrieval and tumor-free margins was 24 ± 7 (range, 29-15) and 8 ± 3 (range, 6-12) cm, respectively.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2007 Mar;204(3):439-46 [17324779.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Colorectal Dis. 2011 Apr;13(4):393-8 [20002691.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):498-504 [18468803.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Gastrointest Endosc. 2008 Oct;68(4):760-6 [18926184.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):725 [19404081.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1503-7 [17641928.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):111-7 [17185089.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):908-12 [19474690.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]
  • [Cites] Surgeon. 2008 Dec;6(6):357-60 [19110824.001]
  • [Cites] Arch Surg. 2009 Aug;144(8):734-8 [19687377.001]
  • (PMID = 20464415.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Crook TJ, Mead Z, Vadgama B, Malone PS: A case series of nephrogenic adenoma of the urethra and bladder in children: review of this rare diagnosis, its natural history and management, with reference to the literature. J Pediatr Urol; 2006 Aug;2(4):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case series of nephrogenic adenoma of the urethra and bladder in children: review of this rare diagnosis, its natural history and management, with reference to the literature.
  • Nephrogenic adenoma (NA) is a rare benign tumour of the urinary tract and is found most commonly in the bladder.
  • Their diagnostic and management features in the context of differential diagnosis and natural history are discussed.
  • A 3-year-old girl presented with recurrent urinary tract infections (UTIs) and haematuria.
  • An ultrasound scan suggested a large bladder tumour, which was biopsied cystoscopically, and histology confirmed an NA.
  • She then underwent open resection of the tumour.
  • A cystoscopy showed a papillary tumour, which was confirmed as NA on histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947630.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. McCleary-Wheeler AL, Williams LE, Hess PR, Suter SE: Evaluation of an in vitro telomeric repeat amplification protocol assay to detect telomerase activity in canine urine. Am J Vet Res; 2010 Dec;71(12):1468-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ANIMALS: 11 dogs with histologic or cytologic evidence of TCC, 10 dogs with benign lower urinary tract disease, and 9 healthy dogs.
  • Telomerase activity was clearly detected in samples collected from 10 of 11 dogs with TCC, 2 of 10 dogs with benign lower urinary tract disease, and none of the 9 healthy dogs.
  • [MeSH-minor] Animals. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Enzyme Stability. Fibroblasts / enzymology. Lung / enzymology. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21117999.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


55. Yoshida S, Masuda H, Ishii C, Saito K, Kawakami S, Kihara K: Initial experience of functional imaging of upper urinary tract neoplasm by diffusion-weighted magnetic resonance imaging. Int J Urol; 2008 Feb;15(2):140-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience of functional imaging of upper urinary tract neoplasm by diffusion-weighted magnetic resonance imaging.
  • OBJECTIVES: Diffusion-weighted (DW) magnetic resonance imaging (MRI) provides functional information widely used in the diagnosis of acute cerebral stroke.
  • We reported our initial experience of this imaging technique of upper urinary tract (UUT) urothelial carcinoma (UC).
  • The last patient was confirmed as experiencing benign stenosis.
  • The apparent diffusion coefficient (ADC) values of renal parenchyma, dilated collecting system, and tumor were calculated.
  • RESULTS: On DW MRI, all nine tumors showed hyperintensity with negligible urinary intensity.
  • The case of benign stenosis had negative DW MRI.
  • The median (range) ADC value of the tumor (0.803 [0.412-0.958] x 10(-3) mm(2)/s) was significantly lower than those of the dilated collecting system (2.19 [1.42-2.40] x 10(-3)) and renal parenchyma (1.28 [0.922-1.45] x 10(-3), respectively (P < 0.01 and P < 0.01).
  • [MeSH-major] Carcinoma / diagnosis. Diffusion Magnetic Resonance Imaging. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269448.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


56. Wiygul JB, Palmer L: Isolated hemangioma causing gross painless hematuria in an adolescent male. Urology; 2010 Aug;76(2):463-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hematuria in children is usually a benign entity, with hypercalciuria being the usual etiology; however, rarer causes also exist, including genitourinary hemangioma.
  • Hemangioma is a benign tumor, which has a tendency to regress spontaneously by the second year of life.
  • Involvement of the urinary tract is rare, and in patients with bladder involvement, an accompanying syndrome such as Sturge-Weber is usually found.
  • [MeSH-major] Hemangioma / complications. Hematuria / etiology. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20163837.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Das D, Wojno K, Imperiale MJ: BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol; 2008 Mar;82(6):2705-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of mutations in the tumor suppressor genes Rb1 and p53, especially in the early stages of the disease, is low compared to those for other cancers.
  • This has led to the hypothesis that a human virus such as BK virus (BKV), which establishes a persistent subclinical infection in the urinary tract and encodes oncoproteins that interfere with these tumor suppressor pathways, is involved.
  • Previously, we detected BKV DNA in the epithelial cells of benign and proliferative inflammatory atrophy ducts of cancerous prostate specimens.
  • Additionally, in normal prostates, T-antigen (TAg) expression is observed only in specimens harboring proliferative inflammatory atrophy and prostatic intraepithelial neoplasia.
  • We further demonstrate that the p53 gene from atrophic cells expressing TAg is wild type, whereas tumor cells expressing detectable nuclear p53 contain a mix of wild-type and mutant p53 genes, suggesting that TAg may inactivate p53 in the atrophic cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Nov;143(5):1389-97 [7901994.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):681-7 [8158699.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5878-82 [8016082.001]
  • [Cites] N Engl J Med. 1994 Nov 10;331(19):1259-64 [7935683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 [7753819.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):790-8 [7677190.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2410-34 [11018010.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1755-65 [8622896.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):13959-67 [8662914.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Aug;90(1):17-23 [8780741.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):15-23 [11243895.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):23-30 [11243896.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1767-73 [11337374.001]
  • [Cites] Virology. 2001 Nov 25;290(2):192-8 [11883184.001]
  • [Cites] Am J Transplant. 2002 Jan;2(1):25-30 [12095052.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):279-87 [12210488.001]
  • [Cites] Prostate. 2002 Dec 1;53(4):263-76 [12430138.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1529-37 [12707036.001]
  • [Cites] J Med Virol. 2003 Sep;71(1):115-23 [12858417.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5192-200 [12910256.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2444-52 [14634448.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):459-77 [14755677.001]
  • [Cites] Genes Dev. 2004 Feb 1;18(3):261-77 [14744935.001]
  • [Cites] Int J Cancer. 1995 Nov 27;63(5):639-45 [7591279.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1126-37 [8622657.001]
  • [Cites] J Virol. 1996 Apr;70(4):2378-86 [8642665.001]
  • [Cites] J Virol. 1996 Oct;70(10):6902-8 [8794333.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1050-5 [8892589.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 15;89(20):1530-6 [9337350.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):600-4 [9421355.001]
  • [Cites] Adv Virus Res. 1998;50:69-99 [9520997.001]
  • [Cites] Virology. 1998 Apr 10;243(2):492-6 [9568046.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2082-8 [10473090.001]
  • [Cites] J Pathol Bacteriol. 1954 Oct;68(2):617-21 [14354565.001]
  • [Cites] Cell. 2005 Jan 14;120(1):7-10 [15652475.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):354-60 [16007533.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7729-45 [16299533.001]
  • [Cites] J Cell Biochem. 2006 Feb 15;97(3):433-47 [16267836.001]
  • [Cites] J Virol. 2006 Feb;80(3):1361-6 [16415013.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2332-7 [16951249.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Oncogene. 2007 Apr 2;26(15):2145-56 [17401423.001]
  • [Cites] Oncogene. 2007 Apr 2;26(15):2157-65 [17401424.001]
  • [Cites] Oncogene. 2007 Apr 2;26(15):2202-11 [17401429.001]
  • [Cites] Crit Rev Clin Lab Sci. 2007;44(3):243-70 [17453919.001]
  • [Cites] APMIS. 2007 Jun;115(6):743-9 [17550383.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jun;4(6):321-32 [17551536.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7031-46 [15258563.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] J Infect Dis. 1973 Dec;128(6):784-7 [4587749.001]
  • [Cites] Infect Immun. 1975 Jun;11(6):1375-81 [166919.001]
  • [Cites] Prog Med Virol. 1976;22:1-35 [62371.001]
  • [Cites] Proc Soc Exp Biol Med. 1976 Oct;153(1):180-6 [186796.001]
  • [Cites] J Gen Virol. 1978 Feb;38(2):369-74 [203656.001]
  • [Cites] J Virol. 1979 Feb;29(2):763-9 [219257.001]
  • [Cites] J Virol. 1979 Mar;29(3):1177-85 [221672.001]
  • [Cites] J Gen Virol. 1982 Dec;63(2):393-403 [6296286.001]
  • [Cites] J Virol. 1984 May;50(2):636-40 [6323765.001]
  • [Cites] Mol Cell Biol. 1985 May;5(5):1043-50 [2987672.001]
  • [Cites] EMBO J. 1985 Jul;4(7):1819-25 [2992946.001]
  • [Cites] J Virol. 1986 May;58(2):680-3 [3009880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5257-61 [3014539.001]
  • [Cites] Biochim Biophys Acta. 1986 Oct 28;865(2):171-95 [3021222.001]
  • [Cites] J Urol. 1987 Jan;137(1):53-6 [2432282.001]
  • [Cites] Virology. 1987 Sep;160(1):169-75 [2820126.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] J Virol. 1989 Feb;63(2):863-72 [2536108.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] J Virol. 1990 Mar;64(3):1182-91 [2154603.001]
  • [Cites] Oncogene. 1990 Mar;5(3):423-6 [2156209.001]
  • [Cites] Virology. 1990 May;176(1):302-5 [2158695.001]
  • [Cites] EMBO J. 1990 Sep;9(9):2885-9 [2167834.001]
  • [Cites] Arch Virol. 1990;113(3-4):221-33 [2171458.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] EMBO J. 1991 Mar;10(3):633-9 [1848177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5523-7 [1648218.001]
  • [Cites] J Cell Biol. 1991 Dec;115(5):1203-12 [1659575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262-6 [1353891.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5323-8 [1327506.001]
  • [Cites] EMBO J. 1992 Dec;11(13):5013-20 [1464323.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):104-9 [8380785.001]
  • [Cites] Virology. 1993 Apr;193(2):1042-6 [8384745.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Oncogene. 1993 Nov;8(11):2987-93 [8414501.001]
  • (PMID = 18160432.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118970; United States / NCI NIH HHS / CA / CA118970
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Nuclear Localization Signals
  • [Other-IDs] NLM/ PMC2259013
  •  go-up   go-down


58. Healy KA, Carney KJ, Osunkoya AO: Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal; 2010;10:1714-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometriosis is characterized by endometrial-like tissue outside the uterus, primarily on the pelvic peritoneum, ovaries, and rectovaginal septum, and, in rare cases, within the urinary tract (1-3%).
  • Although endometriosis is a benign condition, malignant transformation of endometriosis is a well-described phenomenon.
  • Workup revealed a filling defect in the native left mid-ureter secondary to a large 2.5-cm ureteral tumor.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Kidney Transplantation. Ureter / pathology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842317.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


59. Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH: Characterizing components of the Saw Palmetto Berry Extract (SPBE) on prostate cancer cell growth and traction. Biochem Biophys Res Commun; 2009 Feb 13;379(3):795-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Saw Palmetto Berry Extract (SPBE) is applied for prostate health and treatment of urinary tract infections, nonbacterial prostitis and Benign Prostatic Hyperplasia (BPH) in man.
  • An assumption is that SPBE affects tumor cell progression and migration in breast and prostate tissue.
  • The results show for the first time the potential of SPBE, beta-sitosterol and stigmasterol as potential anti-tumor agents.
  • [MeSH-major] Cell Proliferation / drug effects. Plant Extracts / pharmacology. Prostatic Neoplasms / metabolism. Sitosterols / pharmacology. Stigmasterol / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / antagonists & inhibitors. Cyclin-Dependent Kinase Inhibitor p27 / antagonists & inhibitors. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. STIGMASTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059205.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Permixon; 0 / Plant Extracts; 0 / Sitosterols; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 5LI01C78DD / gamma-sitosterol; 99WUK5D0Y8 / Stigmasterol
  •  go-up   go-down


60. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Nephrogenic adenoma is a rare benign lesion of the urinary tract.
  • Owing to its strong association with a history of urinary tract irritation, nephrogenic adenoma was initially thought to originate from urothelial metaplasia; however, no solid proof of this association has been found.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


61. Liu P, Chen CL, Zeng BL, Ma B, Zhang H, Qiu YX, Chen LT: [Study of the injury to the urinary system caused by radiological vascular interventional therapy of obstetrical and gynecological benign diseases]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jan;41(1):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of the injury to the urinary system caused by radiological vascular interventional therapy of obstetrical and gynecological benign diseases].
  • OBJECTIVE: To explore the injuries to the urinary system caused by uterine artery embolization (UAE) for treatment of obstetrical and gynecological benign diseases, including the classification, aetiology, therapy of the injuries and precaution methods.
  • METHODS: The injuries of the urinary system were reviewed in 960 cases of obstetrical and gynecological benign diseases treated with UAE by our interventional centre.
  • (1) Different degrees of urinary system injuries occurred in 5 of 960 cases, the rate was 0.5%.
  • Correlative injuries could be caused by the retroflow of embolisms into the above arteries. (3) Placement of the catheter into the upper branch of the uterine artery or the tumor vascular net, using microcatheter if necessary and notation of the retroflow in the embolization process could avoid the embolization of bladder and ureter arteries. (4) Totally 506 cases used microcatheter, the ratio was 52.7%.
  • CONCLUSIONS: Injuries to the urinary system could occur in UAE for treatment of obstetrical and gynecological benign diseases, which can be prevented by carefully differentiating the vascular communicating branch and the conditions of branches, and embolization of the upper branch of uterine artery can avoid the injury.
  • [MeSH-major] Embolization, Therapeutic / adverse effects. Genital Diseases, Female / therapy. Urinary Tract / injuries. Urologic Diseases / etiology. Uterus / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635323.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Martino P, Martino D, Palazzo S, Altomare DF, Garofalo L, Battaglia M, Selvaggi FP: Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease. Arch Ital Urol Androl; 2005 Mar;77(1):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between January 1997 and February 2004, 3758 subjects suffering from lower urinary tract symptoms associated with micturition disturbances underwent transrectal ultrasound (TRUS) with a multiplane probe having a variable frequency ranging up to 7.5 MHz and, in the later period, with a transrectal 3D volumetric probe.
  • In 132 cases (27%) it was shown to be a false positive, mainly due to imperfect cleansing of the anal canal; in 284 cases (58%) benign disease was demonstrated (hemorrhoids in 192 patients, abscesses in 21, perianal fistulas in 18, inflamed lymph nodes in 27, polyps in 16).
  • In 34 patients (7%) a malignant tumor was found (infiltration of the anterior rectal wall by a prostatic adenocarcinoma in 13, and a primitive adenocarcinoma of rectal origin in the remaining 21).
  • It can be concluded that transrectal US does not permit a certain diagnosis of the nature of rectal disease, but does raise a diagnostic suspicion that can orient the surgeon to schedule more invasive diagnostic investigations.

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906788.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Mu DW, Zhou LQ, Ding Y, He ZS, Wang Y, He Q, Yang XY: [Clinical utility of fluorescence in situ hybridization improves the sensitivity in the diagnosis of upper urinary tract urothelial carcinoma]. Beijing Da Xue Xue Bao; 2010 Aug 18;42(4):381-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical utility of fluorescence in situ hybridization improves the sensitivity in the diagnosis of upper urinary tract urothelial carcinoma].
  • OBJECTIVE: To assess the clinical utility of a fluorescence in situ hybridization (FISH) assay as a non-invasive method for diagnosing and monitoring urothelial carcinoma (UC) in the upper urinary tract (UUT).
  • METHODS: Urine specimens from 63 consecutive patients with UUT-UC and 69 controls with benign disease were analyzed by means of cytology and FISH.
  • The sensitivities of urine cytology were 35.7% (10/28) for PTa and PT1 tumor,45.7% (16/35)for PT2-4 tumors,with an overall sensitivity of 41.3% (26/63).
  • FISH can promote the diagnosis of UUT-UC, especially for the low stage and low grade cases,it may be a new promising non-invasive method for the diagnosis of UUT-UC.
  • [MeSH-major] Carcinoma / diagnosis. In Situ Hybridization, Fluorescence. Kidney Neoplasms / diagnosis. Kidney Pelvis. Ureteral Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721247.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


64. Harvey TJ, Hughes C, Ward AD, Faria EC, Henderson A, Clarke NW, Brown MD, Snook RD, Gardner P: Classification of fixed urological cells using Raman tweezers. J Biophotonics; 2009 Feb;2(1-2):47-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study has been expanded from our previous live cell study to include the androgen sensitive CaP cell line LNCaP, primary benign prostate hyperplasia (BPH) cells as well as primary urethral cells.
  • [MeSH-major] Optical Tweezers. Spectrum Analysis, Raman / instrumentation. Urinary Tract / cytology
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Cell Size. Discriminant Analysis. Humans. Male. Principal Component Analysis. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tissue Fixation. Urinary Bladder / cytology. Urinary Bladder Neoplasms / pathology. Urine / cytology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ((c) 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).
  • (PMID = 19343685.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


65. Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L: Natural history of urothelial inverted papilloma. Cancer; 2006 Dec 1;107(11):2622-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Inverted urothelial papilloma is an uncommon urothelial neoplasm.
  • Although it is traditionally regarded as a benign tumor, conflicting data on multiplicity, recurrence rate, and association with urothelial carcinoma have left uncertainties concerning its biologic behavior.
  • METHODS: The authors analyzed the clinicopathological characteristics of 75 cases of inverted papilloma in the urinary tract without prior or concurrent urothelial carcinoma to determine its biologic behavior and prognosis, and to correlate these findings with surveillance strategies.
  • Inverted papillomas were located in the urinary bladder (67 cases), prostatic urethra (4 cases), and ureter (4 cases).
  • All other patients were free of tumor recurrence or progression during a mean follow-up of 68 months (range, 2-240 months).
  • CONCLUSIONS: Both the extremely low incidence of tumor recurrence (1%) and strikingly favorable prognosis suggest that inverted urothelial papilloma, when diagnosed according to strictly defined criteria, is a benign urothelial neoplasm not related to urothelial carcinoma.
  • [MeSH-major] Papilloma, Inverted / pathology. Urologic Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17078053.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Tavora F, Fajardo DA, Lee TK, Lotan T, Miller JS, Miyamoto H, Epstein JI: Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol; 2009 Oct;33(10):1540-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Technical advances in endoscopic equipment have led to increased ureteroscopic biopsies of the upper urinary tract, resulting in limited biopsy material.
  • At consultation, the most common diagnoses were benign urothelium (n=25, 32.9%); atypical (n=17, 22.4%); low-grade noninvasive papillary urothelial carcinoma (n=10, 13.2%); and high-grade noninvasive papillary urothelial carcinoma (n=8, 10.5%).
  • In cases where a definitive diagnosis could not be reached on expert review, it was mainly because of the limited size of the biopsy, absence of papillary fronds, crush artifact, and distorted architecture.
  • There were 7 major discrepancies between the outside and second opinion diagnosis, where all of the cases were initially diagnosed as an urothelial neoplasm, yet was non-neoplastic upon review.
  • Strips of urothelium without well-developed fibrovascular cores, polypoid ureteritis/pyelitis, and reactive urothelium mimicked urothelial neoplasms.
  • In 5 of these 7 cases, there was no gross lesion suspicious of a tumor present according to the urologist.
  • Overall, 33 of the 44 (75%) cases with a mass noted by the urologist or by radiography was found to have a neoplasm at follow-up.
  • Conversely, 24 of the 32 (75%) cases without a grossly suspected tumor had no neoplasm at follow-up.
  • The association between the histologic presence of a neoplasm at follow-up and the presence of a clinically suspected tumor was highly significant (P<0.0001).
  • Pathologists need to recognize that in almost 1 of the 4 renal pelvic/ureteral biopsies a definitive diagnosis cannot be made because of the inadequate tissue.
  • Caution must be exercised in the evaluation of these limited specimens, especially in the absence of a clinically suspected tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Endoscopy. Female. Humans. Male. Middle Aged. Urologic Neoplasms / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654502.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Cai T, Salvadori A, Nesi G, Detti B, Tinacci G, Zini E, Bartoletti R: Penile metastasis from a T1b prostate carcinoma. Onkologie; 2007 May;30(5):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In March 1998, the patient underwent prostate surgery for lower urinary tract symptoms related to benign prostatic obstruction.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Disease Progression. Humans. Incidental Findings. Male. Neoplasm Staging. Palliative Care. Penis / pathology. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460419.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


68. Mo ML, Chen Z, Li J, Li HL, Sheng Q, Ma HY, Zhang FX, Hua YW, Zhang X, Sun DQ, Xu ML, Niu RG, Xu JP, Zuo HJ, Liu M, Zhou HM: Use of serum circulating CCNB2 in cancer surveillance. Int J Biol Markers; 2010 Oct-Dec;25(4):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the potential use of circulating CCNB2 in serum in cancer surveillance, we examined relative expression levels of serum circulating CCNB2 mRNA in 103 cancer patients, 19 normal controls, and 40 benign disease patients using real-time quantitative reverse transcriptase polymerase chain reaction.
  • We found that the relative expression level of circulating CCNB2 mRNA in cancer patients was significantly higher (p<0.0001) than that in normal controls and benign diseases group.
  • Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) of 0.87 and 0.83 (p<0.05) in identifying cancer patients' metastasis status in lung and digestive tract cancer, respectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Cyclin B2 / blood. Neoplasms / diagnosis. RNA, Messenger / blood
  • [MeSH-minor] Aged. Case-Control Studies. Digestive System Neoplasms / diagnosis. Digestive System Neoplasms / pathology. Female. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / pathology. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Transcriptional Activation. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21161946.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin B2; 0 / RNA, Messenger
  •  go-up   go-down


69. Herawi M, Parwani AV, Chan T, Ali SZ, Epstein JI: Polyoma virus-associated cellular changes in the urine and bladder biopsy samples: a cytohistologic correlation. Am J Surg Pathol; 2006 Mar;30(3):345-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 762 predominantly voided urine specimens with a cytologic diagnosis of polyoma virus-type change were retrieved from the cytopathology files of the Johns Hopkins Hospital over a 15-year period (1988-2003).
  • Biopsies were available for 33 cases (29 patients) following or preceding the urinary cytology (mean interval, 210 days).
  • The histologic diagnoses of the 33 tissue biopsies were: benign urothelium (n=9), urothelial carcinoma (n=21) and 1 case each of dysplasia, small cell carcinoma, and chronic lymphocytic leukemia involving lamina propria of the bladder.
  • c) polyoma virus changes may originate from sites in the genitourinary tract other than the bladder;.
  • 3) Because some cytologically benign cases of polyoma virus were associated with malignant biopsies, careful morphologic evaluation is required to avoid false-negative urinary cytology samples.
  • The staining was present in only one of four samples from each tumor (0.63%; 2 of 316 tumor spots), which further illustrates the patchy and focal presence of virion containing cells. p53 staining in these two spots was also patchy and confined to rare nuclei.
  • [MeSH-major] Cytodiagnosis. Polyomavirus / isolation & purification. Polyomavirus Infections / diagnosis. Polyomavirus Infections / urine. Urinary Bladder / virology. Urinary Bladder Diseases / virology
  • [MeSH-minor] Adult. Aged. Antigens, Polyomavirus Transforming / metabolism. Biopsy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538054.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Kaplan SA: The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. J Urol; 2005 Jun;173(6):2058
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey.
  • [MeSH-major] Life Style. Prostatic Hyperplasia / epidemiology. Urinary Bladder Neck Obstruction / epidemiology. Urinary Retention / epidemiology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Humans. Italy. Male. Middle Aged. Organ Size. Prostate / pathology. Prostate / physiopathology. Prostate-Specific Antigen / blood. Risk Factors. Urodynamics / physiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879832.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


71. Hori J, Hou K, Kato Y, Saga Y, Hashimoto H, Kaneko S: [A case of a ureteral inflammatory pseudotumor]. Hinyokika Kiyo; 2005 May;51(5):335-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on CT findings, a lower ureteral stricture caused by a benign extraureteral tumor was diagnosed.
  • Retrograde pyelography showed an elliptical filling defect in the lower urinary tract.
  • Ureteroscopy showed that the surface of the tumor was mostly smooth, regular and partially papillary.
  • In December 2003, based on a diagnosis of benign ureteral tumor, we performed partial resection of the right urinary tract and ureterocystoneostomy.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Ureteral Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977601.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


72. Kranjcević K, Marković BB: [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?]. Acta Med Croatica; 2007 Feb;61(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?].
  • [Transliterated title] Tko provodi rano otkrivanje benigne hiperplazije prostate i karcinoma prostate u Hrvatskoj?
  • INTRODUCTION: Benign prostatic hyperplasia (BPH) is the most common benign tumor and prostate cancer is the second most common cause of cancer death in Croatia.
  • Data on the risk factors for BPH and prostate cancer (positive family history, urinary problems), IPSS questionnaire, digitorectal examination, urine test, creatinine and prostate specific antigen blood test were collected from their medical records. chi2-test was used on statistical analysis.
  • Digitorectal examination was not performed at either GP office, and 481 (78.3%) patients received no information about lower urinary tract symptoms.
  • [MeSH-major] Delivery of Health Care. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Croatia. Early Diagnosis. Humans. Male. Middle Aged. Physicians, Family. Urology


73. Nggada HA, Eni UE, Nwankwo EA: Histopathological findings in nephrectomy specimens--A review of 42 cases. Niger Postgrad Med J; 2006 Sep;13(3):244-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 23 (54.8%) were benign and 19(45.2%) malignant.
  • CONCLUSION: There is need to emphasise the importance of early diagnosis and proper treatment of urinary tract infections, since chronic interstitial/pyelonephritis is the commonest indication for nephrectomy in our environment.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Nephrectomy. Pyelonephritis / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278316.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


74. Ferrero Doria R, Huertas Valero E, Coronel Sánchez B, Moreno Pérez F, García Víctor F, Díaz Calleja E: [Inverted papilloma of the upper urinary tract]. Actas Urol Esp; 2005 Apr;29(4):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inverted papilloma of the upper urinary tract].
  • [Transliterated title] Papiloma invertido de tracto urinario superior.
  • Inverted papilloma of the upper urinary tract is a rare tumor and generally considered to be a benign.
  • We present two cases of benign ureteral inverted papilloma.
  • They were discovered after to study a upper urinary infection and a gross hematuria respectively.
  • [MeSH-major] Papilloma, Inverted / pathology. Ureteral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981434.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y: Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer; 2008 Jan 15;122(2):444-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alpha-1 adrenoceptor antagonists are generally prescribed for benign prostate hyperplasia with lower urinary tract symptoms.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. G1 Phase / drug effects. Naphthalenes / pharmacology. Piperazines / pharmacology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adrenergic alpha-Antagonists / pharmacology. Animals. Cell Line, Tumor. Cell Proliferation. Cell Separation. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27. Flow Cytometry. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Receptors, Adrenergic, alpha-1 / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17918159.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 0 / Naphthalenes; 0 / Piperazines; 0 / Receptors, Adrenergic, alpha-1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; R9PHW59SFN / naftopidil
  •  go-up   go-down


76. Ugurlu O, Gonulalan U, Adsan O, Kosan M, Oztekin V, Cetinkaya M: Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results. Urology; 2007 Jul;70(1):55-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the effect on the oncologic outcomes of treatment with transurethral resection of patients with a solitary bladder tumor smaller than 3 cm with a superficial appearance and benign prostatic hyperplasia.
  • METHODS: The follow-up data from 34 men (group 1) who had undergone transurethral bladder tumor resection alone and 31 men who had undergone both transurethral prostate resection and transurethral bladder tumor resection at the same operation (group 2) in our clinic from 1996 to 2004 were retrospectively examined.
  • CONCLUSIONS: According to our results, transurethral prostate resection can be safely performed with transurethral bladder tumor resection simultaneously in selected patients with severe lower urinary tract symptoms and a superficial solitary tumor smaller than 3 cm.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656208.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Feil G, Stenzl A: [Tumor marker tests in bladder cancer]. Actas Urol Esp; 2006 Jan;30(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor marker tests in bladder cancer].
  • To improve early detection of bladder cancer as well as to monitor treatment response and tumor recurrence, bladder tumor markers are eligible.
  • In recent years, the FDA approved non-invasive tumor marker tests ImmunoCyt / uCyt+, BTA TRAK, BTA stat, NMP22, NMP22 BladderChek, and UroVysion have been investigated.
  • The tests demonstrated higher sensitivity for diagnosis of bladder cancer compared to urine cytology.
  • BTA TRAK, BTA stat, NMP22, and NMP22 BladderChek assays are limited by false-positive results in patients with benign urological diseases such as hematuria, urocystitis, renal calculi or urinary tract infections.
  • Due to low specificity BTA TRAK, BTA stat, NMP22, and NMP22 BladderChek should not be used without first ruling out benign or malignant genitourinary disease other than bladder cancer.
  • With the exception of UroVysion achieving 80% sensitivity and 94% specificity, none of these non-invasive tests revealed a high sensitivity and specificity at the same time, which is a main demand to be made on an ideal tumor marker.
  • Insufficient sensitivity along with limited specificity does not allow replacing cystoscopy in diagnosis of bladder cancer or treatment decisions based on a positive test result.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703728.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 60
  •  go-up   go-down


78. Hungerhuber E, Bach E, Hartmann A, Frimberger D, Stief C, Zaak D: Adenocarcinoma of the bladder following nephrogenic adenoma: a case report. J Med Case Rep; 2008;2:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Nephrogenic adenomas are generally considered to be benign lesions, but there remains a risk for malignant transformation.
  • After physical recovery from the accident, he developed a neurogenic bladder and recurrent urinary tract infections.
  • The initial pathologic findings were benign, however, the last resection revealed that the former benign adenoma had transformed into a moderately differentiated adenocarcinoma of the bladder (tumor present but no invasion, multifocal, no lymph nodes involved, no metastasis, grade 2).
  • He subsequently underwent radical cystectomy and has remained tumor-free for the last 4 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jan;139(1):130-1 [3121867.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1987 Mar;29(3):237-41 [3548004.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):268-75 [3706613.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] J Urol. 1984 Aug;132(2):263-5 [6737573.001]
  • [Cites] J Urol. 1981 Dec;126(6):824-6 [6798226.001]
  • [Cites] J Urol. 1996 Jul;156(1):41-4 [8648834.001]
  • [Cites] Urology. 1997 Nov;50(5):690-6 [9372876.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):117-22 [11954029.001]
  • [Cites] N Engl J Med. 2002 Aug 29;347(9):653-9 [12200552.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2381-2 [14634422.001]
  • [Cites] J Urol. 1950 Nov;64(5):657-70 [14785074.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):117-20 [16360424.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1231-7 [17667548.001]
  • [Cites] Northwest Med. 1949 Mar;48(3):182-5 [18114097.001]
  • [Cites] J Urol. 1988 Jan;139(1):45-7 [3275801.001]
  • (PMID = 18485239.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396656
  •  go-up   go-down


79. Hattori S, Takagi K, Uno M, Nezasa S, Komeda H, Fujimoto Y: [Case report of inflammatory pseudotumor that occurred at the ureteropelvic junction]. Hinyokika Kiyo; 2008 Nov;54(11):737-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old woman underwent detailed examinations for hepatic disorders and pancreatic tumor at the Department of Internal Medicine.
  • A tumor mass in her left renal pelvis and a thickened wall in her left ureter were observed on computed tomography (CT) and magnetic resonance imaging (MRI) images.
  • Urinary cytology finding was class III-a; however, malignancy could not be disregarded.
  • Not many inflammatory pseudotumors are found in the urinary tract, and even fewer are manifest in the renal pelvis and ureter.
  • Although inflammatory pseudotumors are generally benign, cases of repeated local recurrence exist.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Kidney Diseases / diagnosis. Kidney Diseases / pathology. Kidney Pelvis. Ureteral Diseases / diagnosis. Ureteral Diseases / pathology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068729.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


80. Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, Sun SZ: Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food; 2008 Jun;11(2):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia.
  • A flaxseed lignan extract containing 33% secoisolariciresinol diglucoside (SDG) was evaluated for its ability to alleviate lower urinary tract symptoms (LUTS) in 87 subjects with benign prostatic hyperplasia (BPH).
  • Maximum urinary flows insignificantly increased 0.43 +/- 1.57, 1.86 +/- 1.08, and 2.7 +/- 1.93 mL/second (mean +/- SE, no statistical significance reached), and postvoiding urine volume decreased insignificantly by -29.4 +/- 20.46, -19.2 +/- 16.91, and -55.62 +/- 36.45 mL (mean +/- SE, no statistical significance reached).
  • [MeSH-minor] Aged. Aged, 80 and over. Butylene Glycols / administration & dosage. Double-Blind Method. Glucosides / administration & dosage. Humans. Male. Middle Aged. Placebos. Plant Extracts / administration & dosage. Quality of Life. Urinary Tract / physiopathology. Urination. Urine

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358071.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butylene Glycols; 0 / Glucosides; 0 / Lignans; 0 / Placebos; 0 / Plant Extracts; 148244-82-0 / secoisolariciresinol diglucoside
  •  go-up   go-down






Advertisement